Yarrow Bioscience, Inc. Common Stock
YARW
48 hedge funds and large institutions have $63M invested in Yarrow Bioscience, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 19 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
8% less funds holding
Funds holding: 52 → 48 (-4)
42% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 19
42% less capital invested
Capital invested by funds: $110M → $63M (-$46.5M)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.15M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$226K |
| 3 |
BlackRock
New York
|
+$145K |
| 4 |
State Street
Boston,
Massachusetts
|
+$145K |
| 5 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$113K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$24M |
| 2 |
DM
Deerfield Management
New York
|
-$436K |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$388K |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$371K |
| 5 |
JP Morgan Chase
New York
|
-$323K |
YARW Hedge Fund Activity: Q3 2019 in Review
48 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q3 2019, worth a combined $63M — down 42% from $110M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of YARW and 3 opened new positions — a net loss of 4 holders — while 19 trimmed existing stakes and 11 added.
The largest buyer was DAFNA Capital Management, adding an estimated $1.15M. The largest seller was Vivo Capital, exiting entirely with an estimated $24M sold.
- 48 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q3 2019, down from 52 in Q2 2019.
- Funds reported $63M of Yarrow Bioscience, Inc. Common Stock stock for Q3 2019, down 42% quarter-over-quarter.
- 3 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q3 2019 and 7 closed out, a net change of -4 holders.
- The largest Yarrow Bioscience, Inc. Common Stock buyer in Q3 2019 was DAFNA Capital Management, an estimated $1.15M added.
- The largest Yarrow Bioscience, Inc. Common Stock seller in Q3 2019 was Vivo Capital, an estimated $24M sold.
Based on aggregated 13F filings for Q3 2019.